We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 25, 2021

Sacituzumab Govitecan for Patients With Epithelial Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Sacituzumab Govitecan, a Trop-2–Directed Antibody-Drug Conjugate, for Patients With Epithelial Cancer: Final Safety and Efficacy Results From the Phase 1/2 IMMU-132-01 Basket Trial
Ann. Oncol 2021 Mar 16;[EPub Ahead of Print], A Bardia, WA Messersmith, EA Kio, JD Berlin, L Vahdat, GA Masters, R Moroose, AD Santin, K Kalinsky, V Picozzi, J O'Shaughnessy, JE Gray, T Komiya, JM Lang, JC Chang, A Starodub, DM Goldenberg, RM Sharkey, P Maliakal, Q Hong, WA Wegener, T Goswami, AJ Ocean

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading